Program in Developmental Endocrinology and Genetics, National Institutes of Health, Bethesda, Maryland 20892-1932, USA.
J Clin Endocrinol Metab. 2011 Jan;96(1):E161-72. doi: 10.1210/jc.2010-0319. Epub 2010 Oct 6.
Genetic analysis is commonly performed in patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency.
The objective of the study was to describe comprehensive CYP21A2 mutation analysis in a large cohort of CAH patients.
Targeted CYP21A2 mutation analysis was performed in 213 patients and 232 parents from 182 unrelated families. Complete exons of CYP21A2 were sequenced in patients in whom positive mutations were not identified by targeted mutation analysis. Copy number variation and deletions were determined using Southern blot analysis and PCR methods. Genotype was correlated with phenotype.
In our heterogeneous U.S. cohort, targeted CYP21A2 mutation analysis did not identify mutations on one allele in 19 probands (10.4%). Sequencing identified six novel mutations (p.Gln262fs, IVS8+1G>A, IVS9-1G>A, p.R408H, p.Gly424fs, p.R426P) and nine previously reported rare mutations. The majority of patients (79%) were compound heterozygotes and 69% of nonclassic (NC) patients were compound heterozygous for a classic and a NC mutation. Duplicated CYP21A2 haplotypes, de novo mutations and uniparental disomy were present in 2.7% of probands and 1.9 and 0.9% of patients from informative families, respectively. Genotype accurately predicted phenotype in 90.5, 85.1, and 97.8% of patients with salt-wasting, simple virilizing, and NC mutations, respectively.
Extensive genetic analysis beyond targeted CYP21A2 mutational detection is often required to accurately determine genotype in patients with CAH due to the high frequency of complex genetic variation.
由于 21-羟化酶缺乏,常对先天性肾上腺皮质增生症(CAH)患者进行基因分析。
本研究旨在描述大样本 CAH 患者 CYP21A2 综合突变分析。
对 182 个无关家系的 213 例患者和 232 例父母进行靶向 CYP21A2 突变分析。对经靶向突变分析未发现阳性突变的患者进行 CYP21A2 完整外显子测序。采用 Southern blot 分析和 PCR 方法确定拷贝数变异和缺失。将基因型与表型相关联。
在我们异质的美国队列中,19 名先证者(10.4%)的一个等位基因经靶向 CYP21A2 突变分析未发现突变。测序发现 6 种新突变(p.Gln262fs、IVS8+1G>A、IVS9-1G>A、p.R408H、p.Gly424fs、p.R426P)和 9 种先前报道的罕见突变。大多数患者(79%)为复合杂合子,69%的非经典(NC)患者为经典和 NC 突变的复合杂合子。2.7%的先证者和 1.9%和 0.9%的信息性家系患者存在 CYP21A2 重复单体型、新生突变和单亲二体性。基因型在盐耗竭、单纯男性化和 NC 突变的患者中分别准确预测表型的 90.5%、85.1%和 97.8%。
由于 CAH 患者复杂遗传变异的高频发生,在进行 CYP21A2 突变检测之外,通常需要进行广泛的基因分析以准确确定基因型。